| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-03-18 | Medigene (Germany) Falk Pharma (Garmny) | RhuDex® | primary biliary cirrhosis and other indications in hepatology and gastroenterology | licensing |
Liver diseases - Digestive diseases - Autoimmune diseases | Development agreement |
| 2014-03-17 | MedImmune (USA - global biologics arm of AstraZeneca (UK) biOasis (Canada) | Transcend brain delivery platform | Transciend | Technology - Services | Establishment of a new subsidiary in the EU | |
| 2014-03-17 | Fate Therapeutics (USA - CA) | member of the board of directors | nomination | Rare diseases | Nomination | |
| 2014-03-16 | ONcoDNA (Belgium) National Blood and Cancer Center (Saudi Arabia) | clinical grade molecular diagnostics using the OncoDEEP DX and Clinical cancer panels | Diagnostic - Cancer - Oncology | Collaboration agreement | ||
| 2014-03-14 | Alvotech (Iceland) Finesse Solutions (USA) | manufacturing platform suite | manufacturing |
Production agreement | ||
| 2014-03-13 | Vivalis (now Valneva) (France) Farvet Farmacológicos Veterinarios (Peru) | EB66® cell line for the production of up to three poultry-based veterinary vaccines | licensing |
Veterinary medicine | Licensing agreement | |
| 2014-03-13 | Medimmune (USA - global biologics arm of AstraZeneca (UK) - MD Anderson Cancer Center (USA - TX) | immunotherapy products | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-03-13 | Teva Pharmaceutical (Israel) National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI) (UK) | dementia | collaboration |
Mental diseases - CNS diseases | Clinical research agreement | |
| 2014-03-11 | Esteve (Spain) Genethon (France) | adeno-associated viral vector serotype 9 (NAV rAAV9) containing the human sulfamidase gene | mucopolysaccharidosis type IIIA or Sanfilippo syndrome Type A | development |
Rare diseases | Production agreement |
| 2014-03-11 | Roche (Switzerland) Manchester Academic Health Science Centre (UK) | combination therapies, biomarkers, new drugs, devices | R&D |
Cancer - Oncology - Cardiovascular diseases - Inflammatory diseases - Mental diseases | R&D agreement | |
| 2014-03-11 | Sanofi (France) UCB (Belgium) | anti-inflammatory small molecules | R&D |
Immunological diseases - Inflammatory diseases - Autoimmune diseases | R&D agreement | |
| 2014-03-11 | Caisson Biotech (USA) Novo Nordisk (Sweden) | HEPtune™ drug delivery system | licensing |
Metabolic diseases - Inflammatory diseases - Autoimmune diseases | Licensing agreement | |
| 2014-03-11 | TC BioPharm (UK) Medinet (Japan) | R&D | Cancer - Oncology | |||
| 2014-03-10 | Antabio (France) Argenta (Galapagos subsidiary – UK Belgium) | drug discovery services for novel anti-bacterial agents | R&D |
Infectious diseases | Milestone | |
| 2014-03-10 | Takeda Pharmaceutical (Japan) University College London (UCL) (UK) | gene therapy, cell therapy, stem cell therapy | muscular distrophy, other muscle diseases | R&D |
Rare diseases - Neuromuscular diseases | R&D agreement |
| 2014-03-10 | Bayer HealthCare (Germany) Kythera (USA) | ATX-101 (proprietary formulation of synthetic sodium deoxycholate) | reduction of submental fat (double chin) | commercialisation |
Aesthetic area | Commercialisation agreement |
| 2014-03-10 | Da Volterra (France) BioAster (France) | DACCAR project | Infectious diseases | Collaboration agreement | ||
| 2014-03-07 | Valneva (France - Austria) Emergent BioSolutions (USA - MD) | EB66® cell line | licensing |
Infectious diseases | Licensing agreement | |
| 2014-03-06 | AstraZeneca (UK) - Korea Health Industry Development Institute (South Korea) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2014-03-06 | Redx Pharma (UK) Pierre Fabre Laboratories (France) | small molecule program for an undisclosed oncology target | skin cancers | collaboration option |
Cancer - Oncology | Collaboration agreement |
